Added to YB: 2025-10-28
Pitch date: 2025-10-24
IBRX [bullish]
ImmunityBio, Inc.
+205.93%
current return
Author Info
Company Info
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.
Market Cap
$8.5B
Pitch Price
$2.53
Price Target
N/A
Dividend
N/A
EV/EBITDA
-40.96
P/E
-9.19
EV/Sales
65.83
Sector
Biotechnology
Category
growth
Immunity Bio: The Company That Could Save the World.
IBRX: IL-15 agonist Anktiva reverses lymphopenia (60% success in NSCLC, 80% maintain >1K cells/µL), tripling survival vs standard care. Platform targets immune exhaustion from COVID/aging. CEO Soon sold 2 biotechs for $7.6B, owns 50%+. High risk/insolvent but massive upside if platform scales.
Read full article (9 min)